Previous PSTA Research Sample Clauses

Previous PSTA Research. The original research on PSTA was initiated at a time when the expected outflow TP target concentration from the technology would be 10 µg/L. While the current WQBEL target for the STAs is slightly higher (outflow average of 13 µg/L TP three out of five years), it is clear that to achieve an annual mean value of 13 µg/L, the wetland must be capable of providing sub-13 µg/L outflow levels for a good portion of the operational period. This concentration range appears to be outside the long-term capability of SAV cells established on previously farmed lands (▇▇▇▇▇▇ and ▇▇▇▇▇▇, 2011). A key question, when reviewing results from previous PSTA platforms, is “Does the establishment of a limerock or shell rock substrate in the treatment wetland provide a strong likelihood of attaining annual mean outflow TP levels of 13 µg/L and lower?” Prior to the establishment of the STA-3/4 PSTA Cell, numerous investigations were performed at mesocosm, test cell and field scale using a number of inert substrates (e.g., limerock, shell rock and acid-rinsed sands), and these results are described below. Eighteen mesocosm-scale PSTA treatments have been investigated at STA-1W, 14 of which contained an “inert” substrate, such as sand or limerock. Of these, only three achieved average outflow concentrations below 13 µg/L: a very shallow raceway (9 cm water depth) using local limerock reduced inflow levels of 18 µg/L to 10 µg/L over an 18-month period (▇▇▇▇▇▇ et al., 2004); a slightly deeper treatment (30 cm water depth) with an acid-rinsed sand substrate reduced inflow TPs of 19 µg/L to 11 µg/L (over 12 months) (CH2M-Hill 2003), and; a 60 cm depth shell rock substrate treatment reduced inflows from 19 µg/L to 13 µg/L over 12 months (CH2M-Hill 2003). Two STA-1E mesocosm treatments, one with a 12” Ft. ▇▇▇▇▇▇▇▇ limestone substrate and one with 6” of local limestone over 6” sand, performed relatively well, reducing inflow TP levels of ~25 µg/L to 13 and 9 µg/L, respectively, over 27 months. It is unclear why the ~13 µg/L TP “target” was achieved in only 21% (5 of 14) of the “inert substrate” mesocosm treatments, but it indeed demonstrates that the presence of limerock does not guarantee that ultra-low P levels will be achieved.
View Source
Previous PSTA Research. Modification of the benthic surface (muck removal or limerock addition) to support periphyton growth is expected to be the costliest aspect of construction of a full-scale PSTA facility. Many of the early PSTA studies were designed to examine the effects of substrate character on outflow TP concentration. This points to a key knowledge gap: Does the establishment of a limerock or shell rock substrate in the treatment wetland provide a strong likelihood of attaining annual mean outflow TP levels of 13 µg/L and lower? The previous studies that we examined were conducted across a variety of scales (2 m2 - 40 ha) and tested substrates including muck, sand, local limerock and shell rock, and imported limerock. Across all studies by all investigators, muck-free, calcitic substrates produced long-term (i.e., life of the project) outflow concentrations at or below 13 µg/L in only 8 of 20 treatment groups. Of course, this general assessment pools studies using diverse inflow waters, hydraulic loading rates and operating depths, but it does indicate that the removal of muck alone does not guarantee acceptable performance. The prior PSTA investigations (not including those with the STA-3/4 PSTA Cell) also produced other useful information, particularly by characterizing construction challenges (the importance of elevation control during construction) and operational issues (seepage and flow quantification, types of macrophyte and periphyton) pertaining to PSTA community development.
View Source

Related to Previous PSTA Research

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Clinical Management for Behavioral Health Services (CMBHS) System 1. request access to CMBHS via the CMBHS Helpline at (▇▇▇) ▇▇▇-▇▇▇▇. 2. use the CMBHS time frames specified by System Agency. 3. use System Agency-specified functionality of the CMBHS in its entirety. 4. submit all bills and reports to System Agency through the CMBHS, unless otherwise instructed.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Community Engagement Integration Activities The SP will support the HSP to engage the community of diverse persons and entities in the area where it provides health services when setting priorities for the delivery of health services and when developing plans for submission to the LHIN including but not limited to CAPS and integration proposals.